K. J. Lei, H. Chen, C. J. Pan, J. M. Ward, B. Mosinger et al., Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse, Nat. Genet, vol.13, pp.203-209, 1996.

B. Héron, Y. Mikaeloff, R. Froissart, G. Caridade, I. Maire et al., Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece, Am. J. Med. Genet. A, vol.155, pp.58-68, 2011.

J. I. Wolfsdorf, J. F. Crigler, and . Jr, Cornstarch regimens for nocturnal treatment of young adults with type I glycogen storage disease, Am. J. Clin. Nutr, vol.65, pp.1507-1511, 1997.

D. D. Koeberl, P. S. Kishnani, D. Bali, C. , and Y. T. , Emerging therapies for glycogen storage disease type I, Trends Endocrinol. Metab, vol.20, pp.252-258, 2009.

P. S. Kishnani, S. L. Austin, J. E. Abdenur, P. Arn, D. S. Bali et al., Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics, American College of Medical Genetics and Genomics, vol.16, p.1, 2014.

L. M. Franco, V. Krishnamurthy, D. Bali, D. A. Weinstein, P. Arn et al., Hepatocellular carcinoma in glycogen storage disease type Ia: a case series, J. Inherit. Metab. Dis, vol.28, pp.153-162, 2005.

S. K. Reddy, P. S. Kishnani, J. A. Sullivan, D. D. Koeberl, D. M. Desai et al., Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia, J. Hepatol, vol.47, pp.658-663, 2007.

C. Margini and J. F. Dufour, The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment, Liver Int, vol.36, pp.317-324, 2016.

B. L. Farah, D. J. Landau, R. A. Sinha, E. D. Brooks, Y. Wu et al., Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency, J. Hepatol, vol.64, pp.370-379, 2016.

D. J. Klionsky and S. D. Emr, Autophagy as a regulated pathway of cellular degradation, Science, vol.290, pp.1717-1721, 2000.

, Figure 5. a-fetoprotein Expression in Dog Tumors and Liver (A and B) Afp mRNA level (A) and AFP protein expression (B) were measured in tumors (HCC) of GSD Ia-affected dogs (n = 6, 4) and liver of GSD Ia (n = 3). (C) Immunohistochemical (IHC) staining of tumor for AFP expression. Brown color indicates AFP expression

L. R. Waskowicz, J. Zhou, D. J. Landau, E. D. Brooks, A. Lim et al., Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia, Hum. Mol. Genet, vol.28, pp.143-154, 2019.

A. Takamura, M. Komatsu, T. Hara, A. Sakamoto, C. Kishi et al., Autophagy-deficient mice develop multiple liver tumors, Genes Dev, vol.25, pp.795-800, 2011.

M. Gjorgjieva, J. Calderaro, L. Monteillet, M. Silva, M. Raffin et al., Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia, J. Hepatol, vol.69, pp.1074-1087, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02339527

D. D. Koeberl, B. D. Sun, T. V. Damodaran, T. Brown, D. S. Millington et al., Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia, Gene Ther, vol.13, pp.1281-1289, 2006.

D. D. Koeberl, C. Pinto, B. Sun, S. Li, D. M. Kozink et al., AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia, Mol. Ther, vol.16, pp.665-672, 2008.

E. D. Brooks, D. J. Landau, J. I. Everitt, T. T. Brown, K. M. Grady et al., Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy, J. Inherit. Metab. Dis, vol.41, pp.965-976, 2018.

S. C. Cunningham, A. P. Dane, A. Spinoulas, G. J. Logan, A. et al., Gene delivery to the juvenile mouse liver using AAV2/8 vectors, Mol. Ther, vol.16, pp.1081-1088, 2008.

D. A. Weinstein, C. E. Correia, T. Conlon, A. Specht, J. Verstegen et al., Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum, Gene Ther, vol.21, pp.903-910, 2010.

W. H. Yiu, Y. M. Lee, W. T. Peng, C. J. Pan, P. A. Mead et al., Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy, Mol. Ther, vol.18, pp.1076-1084, 2010.

Y. M. Lee, H. S. Jun, C. J. Pan, S. R. Lin, L. H. Wilson et al., Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy, Hepatology, vol.56, pp.1719-1729, 2012.

X. Luo, G. Hall, S. Li, A. Bird, P. J. Lavin et al., Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector, Mol. Ther, vol.19, pp.1961-1970, 2011.

D. J. Landau, E. D. Brooks, P. Perez-pinera, H. Amarasekara, A. Mefferd et al., In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA, Mol. Ther, vol.24, pp.697-706, 2016.

S. V. Salganik, D. A. Weinstein, T. D. Shupe, M. Salganik, D. G. Pintilie et al., A detailed characterization of the adult mouse model of glycogen storage disease Ia, Lab. Invest, vol.89, pp.1032-1042, 2009.

E. Mutel, A. Abdul-wahed, N. Ramamonjisoa, A. Stefanutti, I. Houberdon et al., Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas, J. Hepatol, vol.54, pp.529-537, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00575314

P. S. Kishnani, E. Faulkner, S. Vancamp, M. Jackson, T. Brown et al., Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia), Vet. Pathol, vol.38, pp.83-91, 2001.

A. Demaster, X. Luo, S. Curtis, K. D. Williams, D. J. Landau et al., Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia, Hum. Gene Ther, vol.23, pp.407-418, 2012.

R. J. Chandler, M. C. Lafave, G. K. Varshney, N. S. Trivedi, N. Carrillo-carrasco et al., Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy, J. Clin. Invest, vol.125, pp.870-880, 2015.

A. Donsante, D. G. Miller, Y. Li, C. Vogler, E. M. Brunt et al., AAV vector integration sites in mouse hepatocellular carcinoma, Science, vol.317, p.477, 2007.

P. R. Wang, M. Xu, S. Toffanin, Y. Li, J. M. Llovet et al., Induction of hepatocellular carcinoma by in vivo gene targeting, Proc. Natl. Acad. Sci. USA, vol.109, pp.11264-11269, 2012.

A. Donsante, C. Vogler, N. Muzyczka, J. M. Crawford, J. Barker et al., Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors, Gene Ther, vol.8, pp.1343-1346, 2001.

G. Y. Kim, Y. M. Lee, J. H. Kwon, J. H. Cho, C. J. Pan et al., Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-a activity restored are at risk of developing hepatic tumors, Mol. Genet. Metab, vol.120, pp.229-234, 2017.

J. H. Cho, G. Y. Kim, B. C. Mansfield, and J. Y. Chou, Hepatic glucose-6-phosphatase-a deficiency leads to metabolic reprogramming in glycogen storage disease type Ia, Biochem. Biophys. Res. Commun, vol.498, pp.925-931, 2018.

Y. M. Lee, T. J. Conlon, A. Specht, K. E. Coleman, L. M. Brown et al., Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia, J. Inherit. Metab. Dis, vol.41, pp.977-984, 2018.

E. D. Brooks, P. S. Kishnani, D. D. Koeberl, and . Lee, Letter to the Editors: Concerning "Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia, J. Inherit. Metab. Dis, vol.41, pp.913-914, 2018.

P. Bell, A. D. Moscioni, R. J. Mccarter, D. Wu, G. Gao et al., Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver, Mol. Ther, vol.14, pp.34-44, 2006.

L. Zhong, N. Malani, M. Li, T. Brady, J. Xie et al., Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction, Hum. Gene Ther, vol.24, pp.520-525, 2013.

R. J. Chandler, M. C. Lafave, G. K. Varshney, S. M. Burgess, and C. P. Venditti, Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for, Human Gene Therapy? Mol. Ther, vol.24, pp.198-201, 2016.

J. Clar, E. Mutel, B. Gri, A. Creneguy, A. Stefanutti et al., Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice, Hum. Mol. Genet, vol.24, pp.2287-2296, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01350897

A. M. Davidoff, C. Y. Ng, J. Zhou, Y. Spence, and A. C. Nathwani, Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway, Blood, vol.102, pp.480-488, 2003.

B. Sun, H. Zhang, L. M. Franco, S. P. Young, A. Schneider et al., Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II, Mol. Ther, vol.11, pp.57-65, 2005.

S. O. Han, G. Ronzitti, B. Arnson, C. Leborgne, S. Li et al., Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ert via immune tolerance induction, Mol. Ther. Methods Clin. Dev, vol.4, pp.126-136, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01432085

R. J. Mural, M. D. Adams, E. W. Myers, H. O. Smith, G. L. Miklos et al., A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome, Science, vol.296, pp.1661-1671, 2002.

P. Perez-pinera, D. G. Ousterout, M. T. Brown, and C. A. Gersbach, Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases, Nucleic Acids Res, vol.40, pp.3741-3752, 2012.

B. Hirt, Selective extraction of polyoma DNA from infected mouse cell cultures, J. Mol. Biol, vol.26, pp.365-369, 1967.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, vol.25, pp.402-408, 2001.